POLR2A rs2228130: What Your Genotype Means
The rs2228130 variant is a genetic change located within the POLR2A gene, which encodes a critical component of the machinery that transcribes DNA into RNA. Research has explored this variant as a potential predictive marker for how patients with non-small cell lung cancer (NSCLC) respond to the chemotherapy drug gemcitabine.
What each genotype means
Typical gemcitabine response profile
This genotype represents the most common genetic state for this variant. Research into this marker is limited, and it is currently unclear if this specific genotype influences how your body processes or responds to gemcitabine treatment. Please discuss your treatment plan and any concerns regarding medication dosing with your oncologist or pharmacist.
This is the most frequent genotype observed across most global populations.
Potential gemcitabine response marker
You carry one copy of the variant allele associated with studies on gemcitabine treatment outcomes in non-small cell lung cancer. The evidence linking this genotype to specific clinical outcomes remains limited and is not currently used to guide standard medical care. Please consult with your healthcare provider to discuss your specific treatment options and medication management.
This genotype is found at varying frequencies depending on ancestry, appearing in a minority of individuals in most studied cohorts.
Potential gemcitabine response marker
You carry two copies of the variant allele identified in research regarding gemcitabine treatment outcomes. Because the evidence strength for this variant is limited, it is not known how this genotype specifically affects your response to therapy compared to others. Always discuss your clinical situation and medication dosing with your oncology team.
This genotype is relatively rare and is observed at low frequencies across most major ancestral populations.
Understanding the POLR2A Gene
The POLR2A gene provides instructions for creating the largest subunit of RNA polymerase II. This enzyme complex is fundamental to life, as it is responsible for transcribing all protein-coding genes in eukaryotic cells into messenger RNA (mRNA). Beyond mRNA, it also synthesizes various non-coding RNA species that are essential for regulating gene expression and processing cellular information. Because of its central role in cellular function, the POLR2A gene is highly conserved across species. In the context of cancer biology, researchers have observed that the dysregulation or elevated levels of POLR2A can support the rapid proliferation and survival of malignant cells. By understanding how this gene functions, scientists aim to identify how variations in its sequence might influence cellular processes, including how cells respond to external stressors like chemotherapy treatments.
What is the rs2228130 Variant?
The rs2228130 variant is a single nucleotide polymorphism (SNP) situated within the POLR2A gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant has been categorized in some research contexts as a non-synonymous change, meaning it may alter the amino acid sequence of the resulting protein. While the gene itself is vital for basic cellular survival, the specific impact of the rs2228130 variant on the function of the RNA polymerase II enzyme remains a subject of ongoing investigation. Geneticists study such variants to determine if they correlate with observable differences in health outcomes or drug responses. Because this variant is located in a gene with such broad and essential responsibilities, researchers are cautious in interpreting its effects, often requiring large-scale studies to confirm whether the variant truly influences clinical phenotypes.
Evidence and Clinical Associations
The association between rs2228130 and gemcitabine treatment outcomes is currently considered to have limited evidence. Gemcitabine is a chemotherapy medication used to treat various cancers, including non-small cell lung cancer (NSCLC). Some studies have investigated whether specific genetic markers, including those in the POLR2A gene, could help predict which patients might experience better or worse responses to this therapy. However, the current body of research is not sufficient to establish this variant as a definitive clinical tool for guiding treatment decisions. The evidence is often derived from specific cohorts, and results can vary significantly between different populations. Because the field of pharmacogenomics is complex, a single SNP rarely acts in isolation. It is important to recognize that while initial findings may show statistical associations, these must be validated through rigorous, large-scale clinical trials before they can be considered for routine medical practice.
Interpreting Your Genetic Information
If you have received information about your rs2228130 genotype, it is essential to understand that this data does not constitute a medical diagnosis or a treatment plan. Genetic variants are only one piece of a much larger puzzle that includes your overall health, the specific characteristics of your cancer, and other environmental factors. You cannot and should not use this information to make decisions about your medication or chemotherapy regimen. If you are undergoing treatment, your oncology team is the only source for personalized medical advice. They consider a wide range of clinical data, including tumor pathology and your personal health history, to determine the most appropriate care. Always discuss any questions you have about your genetic results or your treatment plan with your clinician or a qualified pharmacist, who can provide context based on the most current clinical guidelines.
How common is this variant?
The frequency of the rs2228130 variant varies across different ancestral groups, with specific data often validated in cohorts of patients with non-small cell lung cancer.
Frequently asked questions
Can I use my rs2228130 result to choose my cancer treatment?
No. The evidence linking rs2228130 to gemcitabine response is limited and not currently used in clinical practice to guide treatment selection. Always consult your oncologist regarding your treatment options.
What does the POLR2A gene do?
POLR2A encodes the largest subunit of RNA polymerase II, an enzyme essential for transcribing DNA into mRNA. It is a fundamental component of the machinery that allows cells to function and express genes.
Is rs2228130 a dangerous mutation?
The rs2228130 variant is a common genetic polymorphism, not a rare or inherently 'dangerous' mutation. Most variants of this type have neutral effects on health, and its association with drug response is still being researched.
Where can I find more information about pharmacogenomics?
You can visit resources like the Pharmacogenomics Knowledge Base (PharmGKB) or the CPIC guidelines website. These organizations provide evidence-based information on how genes affect drug responses.
Sources & further reading
Educational information only, last refreshed 9/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2228130?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29